Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant
- 16 September 2019
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (1) , 199-206
Abstract
Outcomes after ASCT are highly variable making it difficult to predict risk of disease progression. We analyzed the impact of clinically available immune-related biomarkers on treatment-free survival (TFS) in 130 patients receiving Mel200 and ASCT. Absolute lymphocyte count (ALC), monocyte count (AMC), neutrophil count (ANC), and immunoglobulin (Ig) levels were collected on day −2 and 90 of ASCT. The lymphocyte–monocyte (LMR) and neutrophil–lymphocyte ratios (NLR) were then derived. At Day +90, we found that low ALC (18 versus 23 months, p = 0.04) or AMC (13 versus 25 months, p = 0.02) predicted for worse TFS. A low LMR predicted for worse TFS (16 versus 52 months, p = 0.004). Patients with two or three suppressed Ig levels had worse TFS (17 versus 51 months, p = 0.04). Median TFS for poor (low LMR and 2–3 suppressed Ig), intermediate, and good (high LMR and 0–1 suppressed Ig) risk groups was 7.5 versus 27 versus 79 months, respectively (p = 0.0004). In a multivariate analysis, a low LMR and suppressed Ig levels were strong independent predictors of poor TFS. We propose an immune score combining these available tests to stratify patients at risk for early progression and identify those who may benefit from intensified post-ASCT consolidation or immunotherapy based approaches.Keywords
This publication has 35 references indexed in Scilit:
- Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsLeukemia, 2018
- Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent InductionJAMA Oncology, 2018
- Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM StudyJournal of Clinical Oncology, 2017
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for MyelomaNew England Journal of Medicine, 2017
- Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myelomaHaematologica, 2017
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple MyelomaJAMA Oncology, 2017
- Long-term prognostic significance of response in multiple myeloma after stem cell transplantationBlood, 2011
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Suppression of polyclonal immunoglobulins in multiple myeloma: Relationship to the staging and other manifestations at diagnosisClinical Immunology and Immunopathology, 1980